Clinical trial
STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of…
NCT00088088 · Synta Pharmaceuticals Corp., Industry · Completed
Key facts
| NCT number | NCT00088088 |
|---|---|
| Title | STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC) |
| Official title | A Phase I/II Trial of STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer (NSCLC) |
| Lead sponsor | Synta Pharmaceuticals Corp., Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Paclitaxel, Carboplatin, STA 4783 |
| Enrollment | 86 |
| Start date | Mar 1, 2004 |
| Completion | Mar 1, 2005 |
| First posted | Jul 21, 2004 |
| Last update posted | Dec 4, 2008 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: